Search
Browse
Statistics
Feeds

CRISPR-MiX: a pooled single-stranded donor strategy to enhance HDR efficiency in human iPSCs

[thumbnail of Original Article]
Preview
PDF (Original Article) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
3MB
[thumbnail of Supplemental Information]
Preview
PDF (Supplemental Information) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
640kB

Item Type:Article
Title:CRISPR-MiX: a pooled single-stranded donor strategy to enhance HDR efficiency in human iPSCs
Creators Name:Baum, Rachel, Telugu, Narasimha, Bruyneel, Arne, Kay, Maryam, Nair, Pooja, Perea-Gil, Isaac, Termglinchan, Vittavat, Bharucha, Nike, Lee, Edina, Mercola, Mark, Diecke, Sebastian and Karakikes, Ioannis
Abstract:CRISPR-Cas9 is widely used to model genetic disorders by introducing or correcting disease-associated mutations in induced pluripotent stem cells (iPSCs) through homology-directed repair (HDR). However, HDR efficiency in iPSCs remains low and is highly dependent on the target locus. Here, we developed CRISPR-MiX, an improved protocol to enhance HDR efficiency in human iPSCs. Using a GFP-to-BFP reporter system, we identified key single-stranded oligodeoxynucleotide (ssODN) donor design parameters, including homology arm symmetry, CRISPR/Cas-blocking mutations, and strand complementarity, which significantly influence HDR outcomes. We applied this approach to introduce pathogenic variants into five genes related to genetic cardiomyopathies. Quantitative analysis of HDR events showed that both the target locus and ssODN design strongly affect HDR efficiency. To address the locus- and design-specific limitations, we established CRISPR-MiX, a pooled ssODN-based method for scarless genome editing using ribonucleoproteins (RNPs) that does not require selection. CRISPR-MiX consistently improved HDR efficiency across multiple loci. This strategy offers a simple, robust, and versatile approach for precise genome engineering in iPSCs, supporting broad applications in disease modeling and functional genomics.
Source:Molecular Therapy Nucleic Acids
ISSN:2162-2531
Publisher:Cell Press / Elsevier
Volume:37
Number:1
Page Range:102820
Number of Pages:1
Date:12 March 2026
Official Publication:https://doi.org/10.1016/j.omtn.2025.102820
PubMed:View item in PubMed

Repository Staff Only: item control page

Downloads

Downloads per month over past year

Open Access
MDC Library